Zyversa Therapeutics Inc 's Cash & cash equivalent grew by 160.33 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Zyversa Therapeutics Inc 's Quick Ratio to 0.02, Quick Ratio remained below Zyversa Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Zyversa Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 3617, from total ranking in the fourth quarter 2025 at 4064.

Explain Quick Ratio?
How much Cash & cash equivalents ZVSA�s has?
What are ZVSA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ZVSA Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	22.78 %	13.39 %	10.6 %	26.96 %	25.26 %
Y / Y Cash & cash equivalent Change	-81.22 %	-92.41 %	467.31 %	42.54 %	-20.75 %
Quick Ratio MRQ	0.02	0.01	0.05	0.01	0.13
ZVSA's Total Ranking	# 3617	# 4064	# 3362	# 3337	# 3172
Seq. Current Liabilities Change	15.74 %	-0.24 %	0.6 %	5.72 %	6.88 %
Seq. Cash & cash equivalent Change	160.33 %	-83.33 %	309.43 %	-89.43 %	5.27 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 407
Healthcare Sector	# 817
Overall Market	# 3617

Quick Ratio Statistics
High	Average	Low
3.35	0.38	0.01
(Dec 31 2021)		(Dec 31 2025)

Financial Statements
Zyversa Therapeutics Inc 's Current Liabilities	$ 15 Millions	Visit ZVSA's Balance sheet
Zyversa Therapeutics Inc 's Cash & cash equivalent	$ 0 Millions	Visit ZVSA's Balance sheet
Source of ZVSA's Sales		Visit ZVSA's Sales by Geography

Cumulative Zyversa Therapeutics Inc 's Quick Ratio

ZVSA's Quick Ratio for the trailling 12 Months

ZVSA Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	18.22 %	18.52 %	17.85 %	14.17 %	6.43 %
Y / Y Cash & cash equivalent TTM Growth	-61.99 %	-31.82 %	-27.25 %	-50.69 %	-52.17 %
Quick Ratio TTM	0.02	0.05	0.08	0.07	0.08
Total Ranking TTM	# 2957	# 3006	# 3184	# 2785	# 3328
Seq. Current Liabilities TTM Growth	5.45 %	3.09 %	2.58 %	6.02 %	5.72 %
Seq. Cash & cash equivalent TTM Growth	-50.43 %	-35.28 %	16.72 %	1.5 %	-11.09 %

Quick ratio ranking by company, industry and sector >> Back to ZVSA Financial Strength Comparisons >> Go to Compare ZVSA Quick Ratio to its Competitors

News about Zyversa Therapeutics Inc Quick Ratio

ZyVersa Therapeutics Receives Equity Research Coverage from Noble Capital Markets: Quick Ratio Falls to New Company Low in Wake of Increased Current Liabilities

In a recent announcement, ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company, revealed that Noble Capital Markets has initiated company-sponsored equity research coverage. This news comes as ZyVersa continues to develop first-in-class drugs for the treatment of patients with renal and inflammatory diseases who have unmet medical needs.
To access the full report authored by Noble Capital Markets Senior Research Analyst Robert LeBoyer, along with news and advanced market data on ZyVersa Therapeutics, interested parties can visit Channelchek.com.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q1 2026 to $14.74 millions, cumulative Quick Ratio decreased to 0.02 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 400 other companies have achieved higher Quick Ratio than Zyversa Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2957, from total ranking during the twelve months ending fourth quarter 2025 at 3006.

Explain Quick Ratio?
How much Cash & cash equivalents ZVSA�s has?
What are ZVSA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 401
Healthcare Sector	# 823
Within the Market	# 2957

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.97	0.21	0.02
(Jun 30 2022)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Os Therapies Incorporated	0.05	$ 0.918 Millions	$ 18.331 Millions
Citius Oncology Inc	0.04	$ 2.633 Millions	$ 58.812 Millions
Abvc Biopharma Inc	0.04	$ 0.203 Millions	$ 5.393 Millions
IMPACT BIOMEDICAL INC.	0.03	$ 0.020 Millions	$ 0.584 Millions
Provectus Biopharmaceuticals Inc	0.03	$ 0.224 Millions	$ 7.242 Millions
Evofem Biosciences Inc	0.03	$ 2.379 Millions	$ 78.752 Millions
Gridai Technologies Corp	0.02	$ 0.386 Millions	$ 16.232 Millions
Aditxt Inc	0.02	$ 0.269 Millions	$ 11.452 Millions
China Pharma Holdings Inc	0.02	$ 0.168 Millions	$ 7.268 Millions
Northwest Biotherapeutics Inc	0.02	$ 1.786 Millions	$ 82.973 Millions
Lakewood-Amedex Biotherapeutics Inc.	0.02	$ 0.012 Millions	$ 0.548 Millions
Zyversa Therapeutics Inc	0.02	$ 0.303 Millions	$ 14.739 Millions
Sunshine Biopharma Inc	0.01	$ 0.072 Millions	$ 5.878 Millions
Lftd Partners Inc	0.01	$ 0.054 Millions	$ 4.543 Millions
Semnur Pharmaceuticals Inc	0.01	$ 0.103 Millions	$ 10.380 Millions
Neonc Technologies Holdings Inc	0.01	$ 0.139 Millions	$ 16.288 Millions
Cnbx Pharmaceuticals Inc	0.00	$ 0.012 Millions	$ 2.548 Millions
Cdt Equity Inc	0.00	$ 0.100 Millions	$ 21.636 Millions
NIKA PHARMACEUTICALS, INC	0.00	$ 0.002 Millions	$ 0.332 Millions

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.